# AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

Study · id `cardio:ct-nct07555730` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07555730](<https://clinicaltrials.gov/study/NCT07555730>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07555730

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07555730. Randomized; no masking; primary purpose treatment. Start 2026-04-30 (anticipated); primary completion 2028-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07555730, source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)
- Planned start: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT07555730, source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)
- Primary completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07555730, source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)
- Completion: 2028-09-30 (anticipated) (ClinicalTrials.gov record NCT07555730, source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07555730, source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07555730-2026-04-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
- Condition: Overweight or Obesity; Type 2 Diabetes
- Condition: Weight Loss Maintenance
- Intervention (Behavioral): AI assisted multi-domain lifestyle intervention
- Intervention (Drug): Tirzepatide
- Lead sponsor: Huazhong University of Science and Technology
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: Huazhong University of Science and Technology (`cardio:org-huazhong-university-of-science-and-technology`)

## Provenance

Content hash: 7c810c6645d1bc2ad66fa4cd8cbfeffaa528f305c57d904524b9a96e3d6a5784
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
